Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B0AX
|
|||
| Former ID |
DCL000127
|
|||
| Drug Name |
HIF-1alpha
|
|||
| Synonyms |
Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; UNII-NA856793UT; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 4 | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Enzon
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H24N6O3
|
|||
| Canonical SMILES |
CC(C)(C)NC(=O)NC1=C(C=C2C=NC(=NC2=N1)N)C3=CC(=CC(=C3)OC)OC
|
|||
| InChI |
1S/C20H24N6O3/c1-20(2,3)26-19(27)25-17-15(8-12-10-22-18(21)24-16(12)23-17)11-6-13(28-4)9-14(7-11)29-5/h6-10H,1-5H3,(H4,21,22,23,24,25,26,27)
|
|||
| InChIKey |
NHJSWORVNIOXIT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 192705-79-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8033179, 11060515, 14854492, 39300757, 47657088, 48179700, 53574908, 53787731, 56365793, 57361278, 103233153, 113908744, 121362001, 128702671, 134338810, 134340344, 139404107, 162248829, 162809377, 163685982, 164764079, 175612715, 180401149, 198956848, 204362263, 223369823, 227477539, 251918555, 252808770
|
|||
| ChEBI ID |
CHEBI:156259
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00880672) Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate. U.S. National Institutes of Health. | |||
| REF 2 | Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024. | |||
| REF 3 | A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008 Nov;7(11):3598-608. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.